Image pharmaphorum Editor R&D Strength in numbers: Because having a rare disease isn’t rar... Rare doesn’t mean insignificant – in fact more people live with a rare disease than with cancer and AIDS combined. Event coverage eyeforpharma Barcelona day one Day one: Tuesday 12 March Highlights include: Views & Analysis eyeforpharma barcelona day two Day two: Wednesday 13 March Views & Analysis eyeforpharma barcelona day three Day three: Thursday 14 March Highlights include: Load more results
R&D Strength in numbers: Because having a rare disease isn’t rar... Rare doesn’t mean insignificant – in fact more people live with a rare disease than with cancer and AIDS combined.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
